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Background: Spinal cord injury is a progressive process that initially causes 
abnormal nerve connections. Following spinal cord injury, the spinal cord is 
impaired after which cell death and apoptosis occurs. Primary damage happens 
in the spinal cord due to the demyelization of the large axons. Cell therapy is 
among the new strategies that have been considered for the treatment of neural 
injuries in recent years. 
 
Aim: In this narrative review article, we discuss "Cell Therapy" as a new and 
safe strategy for the treatment of spinal cord injury. we are going to explain the 
epidemiological and pathophysiological aspects of spinal cord injuries (SCI) as 
well as SCI experimental and clinical stem cell strategies. 
 
Conclusion: There are several promising advancements and findings in the 
field of stem cell biology and cell reprogramming, with the aim of treating 
patients with SCI via stem cell therapy. We reviewed critical issues for clinical 
translation and we also provided a commentary on recent developments such as 
termination of the first human embryonic stem cell transplantation trial in 
human SCI. 
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Spinal cord injuries (SCIs) account for 
approximately 10% of injuries to the nervous 
system. Although these injuries are not usually 
severe, they have devastating effects on social, 
psychological, and medical dimensions of 
one’s life for a long time or even until the end 
of their life (1).  
Spinal cord injury arises from various causes 
including crashes, hard sports and occupational 
injuries, inflammatory processes, and 
discopathies.  In Iran, about 50,000 people live 
with spinal cord injury, of whom 2,100 are 
veterans of war (2). Spinal cord injuries are 
usually caused by severe mechanical trauma to 
the spinal cord, causing cardiovascular 
problems, venous thrombosis, osteoporosis, 
pressure ulcers, and neuropathic disorders. 
These injuries cause brain blood dysfunction 
and lead to the release of inflammatory factors 
and subsequent activation of the glial cells that 
ultimately cause spinal cord necrosis (3).  
The inflammation process initially begins with 
the introduction of lymphocytes, neutrophils, 
and monocytes to the site of the lesion. These 
cells destroy digestive remnants and remove 
dead cells. The cascade of inflammation 
ultimately results in cyclic activation of 
cytokine and chemo-like inflammatory factors 
that cause apoptosis, demyelination, loss of 
axons, and degeneration (4). 
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The inflammatory cells destroy the spinal cord 
through secreting the matrix metalloproteinase 
to the site of the lesion [5]. On the other hand, 
macrophages result in neuronal regeneration 
and spinal cord repair via phagocytosis and 
release of protective cytokines such as FGF, 
NGF, and NT3 (6). When the spinal cord injury 
occurs, oligodendrocytes act faster than all 
other cells. They promote apoptosis and 
necrosis and cause myelin to disappear in both 
ascending and descending pathways.  
The exact mechanism of apoptosis of 
oligodendrocytes is still not fully understood. 
FAS receptor, which is located on the surface 
of oligodendrocytes, is activated through the 
FAG ligand by microglial cells and triggers the 
apoptotic cascade (7,8). After an injury to 
oligodendrocytes, some inhibitory factors, 
including OMGp, MAG, Nogo-A, which are 
secreted by these cells, inhibit axonal growth 
(9, 10). The next target is the neurons whose 
axons are thinned and achromatized.  
The transmission of the nerve signal becomes 
disturbed and it loses the ability to guide 
neuronal impulses. Several means have been 
proposed to interfere in this process including 
reintroduction of myelin by stem cells the use 
of neurotrophic enriched stem cells. The 
factors, secreted from these cells, constitute the 
basis for their role in providing faster recovery, 
though the simultaneous use of more than one 
method known as combination therapy may be 
more effective. 
In cell therapy, various cellular sources are used 
for myelination, where the cell therapy strategy 
for a particular disease, to a great extent, 
depends on the complexity of the anomaly. 
Nowadays, cell therapy is considered an 
important strategy in restorative medicine. In 
tissue engineering, cells are definitely the most 
important part of the reconstruction and repair 
of the patient's tissue. The decisive factor is the 
need for reliable cellular resources, from multi-
power cells that can be captured at a low death 
rate, plus a precise control while well-placing 
the cells in the target tissue. 
Pathophysiology 
The spinal cord injury consists of primary and 
secondary phases. In the first stage, motor, 
sensory, and autonomic functions become 
impaired while in the second stage, sequential 
events and molecular cascades happen at the 
site of the lesion, leading to inflammation, 
production of free radicals, necrosis, apoptosis, 
and astrogliosis.  
Damaging factors are divided into two groups: 
a) Factors of external origin such as sudden and 
severe blows, driving accidents, falling, birth-
related injuries, bullet injuries, and injuries 
caused by exercise; b) Factors of internal origin 
such as cerebrovascular accidents, spinal cord 
tumors, infections, myelitis, vascular disorders, 
degenerative changes, hematoma, rupture of 
disc, molybdenum scoliosis, spinal cord fluid 
disorders, and spinal cord inflammation (11, 
12). 
 
Types of spinal cord injury 
Spinal cord injuries are divided according to the 
type of lesion and the degree of involvement. 
The degree of injury to the spinal cord is 
different given the severity and type of injury. 
The lesions created in the spinal cord are 
classified as follows: a) Concussion which 
causes mild nervous symptoms and develops 
after several hours; b) Contusion that leads to 
edema and surface hemorrhage of the spinal 
cord; and c) Compression which is associated 
with severe edema and ischemia leading to 
necrosis.  
This type of lesion may be permanent or slowly 
resolved after a while. Complete spinal cord 
injury results in permanent destruction of all 
physiological activities of the spinal cord below 
the site of the lesion. This lesion may be caused 
by wounding back, rotating and compressing 
the spinal cord (14). 
 
Spinal cord injury stages 
Acute: Symptoms include vascular 
pathological changes and changes in blood 
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pressure in the grey region of the lesion area. It 
begins immediately after the trauma and lasts 
for several hours (15). Due to the effect of free 
radicals, the capillary and vascular walls of the 
perinatal region become defective. With the 
destruction of the vascular wall, a pathway 
opens for the movement of blood cells. 
Subacute: As bleeding continues in the spinal 
cord, more cells die and the number of 
cytoplasmic reticulations increases in microglia 
cells. They express molecules such as antigens 
I and II and C3 receptor plus macrophages 
activator markers. Astrocytes grow larger than 
usual and activate the opioid and lysozyme 
enzymes (16). 
Chronic: A few days after the spinal cord 
injury, a cystic area appears at the site of the 
lesion. This cyst is usually connected to the 
central canal and is full of cerebrospinal fluid 
(CSF). Macrophages are not present anymore. 
A week after injury, scar tissue which is a dense 
network of cytoplasmic astrocytes appears in 
the region. The inflammatory cells and 
meningeal cells participate in the development 
of this network. The resulting destruction of 
myelin causes a blockage in the transmission of 
sensory and motor data. The rate of myelin 
destruction is very important for estimating the 
prognosis of spinal cord injury (17). 
 
Cell therapy 
Recently, cell therapy has been considered as an 
important means in the repair of spinal cord 
injury in the secondary phase. Although the 
multifactorial treatment process should not be 
overlooked in medical treatments and 
rehabilitation activities, stem cells are new 
candidates for this process. These cells are the 
most important part of the reconstruction and 
repair of the patient's tissue (18). There are 
different types of stem cells which come from 
different sources and have various applications 
in the treatment of spinal cord injury. Various 
cells have been used for transplantation in 
demyelinated models of spinal cord injury. 
They include oligodendrocytes or their 
precursors (19), Schwann cells (20), olfactory 
plating cells, and adult or induced pluripotent 
stem cells (21). Nevertheless, the possibility of 
differentiating into unwanted cells, tumor 
formation, executive and ethical issues, social 
intolerance (22), and most importantly, the 
possibility of triggering inflammatory and 
immunological responses have limited the use 
of these methods (23).  
 
Bone marrow stromal stem cells 
By examining different cellular sources for 
transplantation, it is clear that fetal stem cell 
transplantation is not a suitable method for the 
treatment of neurodegenerative diseases. In 
addition to achievement of non-consistent 
results, there are ethical and executive issues in 
their use (23).  
Observations suggest that Bone marrow 
stromal stem cells (BMSCs) in rats and humans 
retain the ability to differentiate into non-
mesenchymal derivatives including neurons. 
There are several recent reports about the 
application of BMSCs for creating neuronal 
cells such as neurons and astrocytes both in 
vitro and in vivo. These results, coupled with 
the limitations of the use of embryonic stem 
cells and the limited availability of adult stem 
cells in therapeutic applications, have added 
value to the importance of further research on 
the use of BMSCs. Bone marrow mesenchymal 
cells (MSCs) are now considered as a source of 
adult stem cells for the treatment of 
neurological diseases, and research in this field 
has become widespread. These cells are mainly 
used in two general forms for transplantation in 
the lesions. A team of researchers introduced 
these cells into a diseased animal without 
induction. The researchers found that BMSCs 
had the ability to differentiate into glial and 
neuronal cells in vivo; after direct injection of 
these undifferentiated cells in the brain and the 
ventricles, they still survived and expressed 
some glial and neuronal markers (24,25,26). 
Note that recent studies have shown that BMSC 
cells are able to secrete most of the neurotropic 
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factors, such as BDNF, NT3, NGF, CNTF, etc. 
In this case, it seems that these cells are superior 
to be used as neuron prophylactic cells and a 
means for nerve injury repairs (27). BMSCs 
transplanted through the intra-spinal injection 
into the hemisection SCI in rats can engage in 
reinsertion of parts of the demineralized spinal 
cord and improve the movement (28). 
 
Neural stem cells 
Neural stem cells (NSCs) are found mainly in 
the epidermal regions of the ventricles and the 
central canal of the spinal cord (28). They 
express a developmental marker of 
neuroepithelial cells (29). Nestin is by far the 
best marker for in vivo neuro-proliferative 
neuronal cells, although it is difficult to trace in 
vivo (30, 31). These cells are multiplicative and 
integrate BrdU into their DNA. BrdU is an open 
thymidine analog which can be replaced in 
cellular phase S; as such, its traceability reflects 
the presence of proliferating cells (32).  
Recent studies have suggested that stem cells of 
the sub-ventricular regions can be activated in 
response to various pathological signals such as 
trauma, ischemia, inflammation, 
neurodegeneration, and loss of myelin (33). 
These NSCs can relocate from their natural path 
to the injury region and become converted into 
a particular cell phenotype (34). Stereotypically 
derived NSCs can be in the form of a sphere 
called Induced Indoor 10 hours post induction. 
Then after 1 hour, they move towards each 
other and form a perfect globe after one day 
(35). Several studies have shown that NSCs are 
able to migrate to areas affected by the injury 
and convert into oligodendrocyte in a variety of 
animal models (36). 
 
Oligodendrocyte 
Identification of the origin and development of 
the oligodendrocytes is important to understand 
the demyelination and re-myelination processes 
(37). According to the recapitulation 
hypothesis, the repair process involves the re-
use of similar programs that occur during the 
developmental process (38). The purpose of 
regenerative therapies is to re-initiate 
myelination and prevent the formation of bare 
axons, which is functionless (37). Repeated 
myelination is essential for the survival of the 
exons and their activity (39).  
The central nervous system of the adult 
population has the capacity for re-myelination 
in response to a myelin-breaking event, but the 
newly formed myelin usually lacks the 
appropriate thickness and length (37). The 
surviving oligodendrocytes at the site of the 
lesion are not able to make myelin (40). Myelin 
is also made by oligodendrocytes that extend 
throughout the brain and the spinal cord, and 
replenish in response to the loss of myelin. 
After migration, they fill the demyelinate 
region. In healthy adults, the oligodendrocytes 
in the white matter form fixed populations that 
are rarely divided and do not participate in the 
oligodendrocyte replacement period and are 
often silent. However, these cells are activated 
in response to injury and begin to proliferate 
(41). 
Inflammatory environments in spinal cord 
injuries induce apoptosis of oligodendrocyte 
precursor cells (42). FAS receptor, which is 
located on the oligodendrocyte surface, is 
activated by FAG ligand via microglial 
activation cell and triggers apoptotic cascade 
(7). Myelin lesions in spinal cord injuries 
inhibit the process of myelination and axonal 
regeneration by expressing myelin proteins 
such as Nogo, MAG, and MOG, which are 
collectively referred to as myelin inhibitory 
factors (43). A number of studies have reported 
that re-myelination could occur as a result of the 
transplantation of oligodendroglia cells, 
Schwann cells, olfactory epithelial cells, and 
various types of stem cells and their derivatives 
(44). In contrast to other studies, it has been 
shown that in demyelinated models, 
endogenous oligodendrocytes or 
oligodendrocytes that are implicated in re-
myelination are not functional (33,34). Studies 
suggest that a real improvement in the 
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functioning of the spinal cord myelination may 
be achieved through reinsertion of healthy 
axons. Studies have also shown that 
oligodendrocytes derived from ESC cells can 
mimic the non-adult CNS ones (35). 
 
Adipose stem cells 
The adipose stem cells (ADSC) in the culture 
medium are similar to fibroblastic cells and 
stromal cells of the bone marrow. ADSC have 
the ability to differentiate into cells with 
mesodermal tissue origins, such as fatty, 
cartilage, bone, and other cells. They also can 
transdifferentiate into neural cells. Research 
has shown that direct injection of ADSC into 
SCI models transforms these cells to neuronal 
cells. These cells improved the symptoms in the 




Neurogolins constitute a family of growth 
factors including NGF, NDF, HRG, PDGF, and 
bFGF. Neurogolins interfere with the growth 
and differentiation of various histological 
groups including epithelial, oligodendrocyte 
and Schwann cells. Recent findings highlight 
the major roles of neurogolins and their 
receptors in regulating cell numbers and 
determining the fate of the cell during cell 
therapy. These molecules also account for the 
growth of oligodendrocyte cells. It seems that 
GGFs are unique among growth factors as they 
can determine the fate of oligodendrocytes and 
glial cells (45). 
 
Schwann cells 
Schwann cells are the glial protective cells of 
the peripheral nervous system, which are 
responsible for making myelin around the 
axons. These cells are responsible for the 
regeneration of axons and re-myelination after 
injury. Schwann cell implantation into the 
damaged spinal cord produces Neurotrophins 
and leads to neuron survival as well as growth 
of the exons. These cells were the first to be 
used in the treatment of spinal cord injury. 
Zamini et al observed Schwann cells derived 
from mesenchymal stem cells. They injected 
them into a spinal cord hemisection model and 
reported improved motor function in 
experimental rats (46,47). 
 
Conclusion 
Results have suggested that cell therapy is one 
of the best ways to treat spinal cord injury in the 
future and is one of the best sources of stem 
cells for this adult stem cell process which is 
free from tumorigenicity and immunization. 
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